Skip to main content

Advertisement

Table 6 Optimal HBV-derived HLA class I restricted CTL epitopes

From: Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot"

Protein HLA Restriction Sequence Position Reference
Core A2 FLPSDFFPSV 18–27 [84]
Core A2 CLTFGRETV 107–115 [85]
Core A2 VLEYLVSFGV 115–124 [85]
Core A2/A24 EYLVSFGVW 117–125 [86, 87]
Core A2 ILSTLPETTV 139–148 [86]
Core A33/A68 STLPETTVVRR 141–151 [88]
Core A2 AILSKTGDPV 152–161 [89]
Env A2 LLDPRVRGL 131–139 [85]
Env A2 VLQAGFFLL 177–185 [90]
Env A2 FLLTRILTI 183–191 [91]
Env A2 SLNFLGGTTV 201–210 [92]
Env A2 FLGGTPVCL 204–212 [89]
Env A2 LLLCLIFLL 250–258 [86]
Env A2 LLCLIFLLV 251–259 [92]
Env A2 LLDYQGMLPV 260–269 [92]
Env A2 LVLLDYQGML 269–278 [85]
Env A2 VLLDYQGML 270–278 [85]
Env A2 LLDYQGMLPV 271–280 [85]
Env A2 WLSLLVPFV 335–343 [92]
Env A2 LLVPFVQWFV 338–347 [92]
Env A2 GLSPTVWLSV 348–357 [92]
Env A2 SIVSPFIPLL 370–379 [89]
Env A2 LLPIFFCLWV 378–387 [92]
Env A2 ILSPFFFLPLL 382–390 [85]
x-Protein A2 VLCLRPVGA 15–23 [93]
x-Protein A2 TLPSPSSSA 36–44 [93]
x-Protein A2 HLSLRGLFV 52–60 [93]
x-Protein A2 VLHKRTLGL 92–100 [93]
x-Protein A2 AMSTTDLEA 102–110 [93]
x-Protein A2 CLFKDWEEL 115–123 [93]
Pol A24 LYSSTVPVF 62–70 [90]
Pol A2 GLSRYVARL 455–463 [90]
Pol A2 YMDDVVLGA 551–559 [91]
Pol A2 FLLSLGIHL 575–583 [90]
Pol A24 KYTSFPWLL 756–764 [87]
Pol A2 ILRGTSFVYV 773–782 [91]
Pol A2 SLYADSPSV 816–824 [91]